Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.45 |
| ▸ | MGLL | Q99685 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | GBA1 | P04062 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11847945 | 1.00 | ALOX5 (0.46) | ALOX5GAAFAAHMGLLL3MBTL1 | |
| SCHEMBL11851404 | 1.00 | ALOX5 (0.46) | ALOX5GAAFAAHMGLLL3MBTL1 | |
| SCHEMBL8967917 | 1.00 | ALOX5 (0.46) | ALOX5GAAFAAHMGLLL3MBTL1 | |
| SCHEMBL664937 | 1.00 | ALOX5 (0.46) | ALOX5GAAFAAHMGLLL3MBTL1 | |
| Laurocapram SCHEMBL23347 | 1.00 | ALOX5 (0.46) | ALOX5GAAFAAHMGLLL3MBTL1 | |
| SCHEMBL10427239 | 1.00 | ALOX5 (0.46) | ALOX5GAAFAAHMGLLL3MBTL1 | |
| SCHEMBL10427195 | 1.00 | ALOX5 (0.46) | ALOX5GAAFAAHMGLLL3MBTL1 | |
| SCHEMBL9003902 | 1.00 | ALOX5 (0.46) | ALOX5GAAFAAHMGLLL3MBTL1 | |
| Laurocapram SCHEMBL2150444 | 1.00 | ALOX5 (0.46) | ALOX5GAAFAAHMGLLL3MBTL1 | |
| SCHEMBL11855053 | 1.00 | ALOX5 (0.46) | ALOX5GAAFAAHMGLLL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2531229-B1 | MEDICINE PRODUCT WITH A PARTICLE-FREE COATING RELEASING AN ACTIVE SUBSTANCE | HEMOTEQ AG (DE) | 2014-12-31 | — | — | EP | claimed |
| CN-102905735-B | Medical product with particle-free coating releasing active substance | HEMOTEQ AG | 2014-12-03 | — | — | CN | claimed |
| US-20130245058-A1 | MEDICAL PRODUCT WITH A PARTICLE-FREE COATING RELEASING AN ACTIVE SUBSTANCE | HEMOTEQ AG (DE) | 2013-09-19 | — | — | US | claimed |
| CN-102905735-A | Medical product with particle-free coating releasing active substance | HEMOTEQ AG | 2013-01-30 | — | — | CN | claimed |
| EP-2531229-A2 | MEDICAL PRODUCT WITH A PARTICLE-FREE COATING RELEASING AN ACTIVE SUBSTANCE | Hemoteq AG (DE) | 2012-12-12 | — | — | EP | claimed |
| WO-2011147408-A2 | MEDICAL PRODUCT WITH A PARTICLE-FREE COATING RELEASING AN ACTIVE SUBSTANCE | HEMOTEQ AG (DE) | 2011-12-01 | — | — | WO | claimed |
| US-20030134420-A1 | Methods and compositions for gene delivery | IMMUNE RESPONSE CORPORATION, THE | 2003-07-17 | — | — | US | claimed |
| WO-2001060415-A1 | METHODS AND COMPOSITIONS FOR GENE DELIVERY | THE IMMUNE RESPONSE CORPORATION (US) | 2001-08-23 | — | — | WO | claimed |
| EP-0435436-B1 | Transdermal flux enhancers in combination with iontophoresis in topical administration of pharmaceuticals | PFIZER (US) | 1994-01-12 | — | — | EP | claimed |
| US-5196410-A | Penetration agents | PFIZER INC. (US) | 1993-03-23 | — | — | US | claimed |
| EP-0435436-A2 | Transdermal flux enhancers in combination with iontophoresis in topical administration of pharmaceuticals | PFIZER INC. (US) | 1991-07-03 | — | — | EP | claimed |
| US-5023085-A | Using 1-alkylazacycloheptan-2-one or substituted cis-olefin as dermal penetration enhancer | PFIZER INC. (US) | 1991-06-11 | — | — | US | claimed |
| US-4959365-A | PENETRATION ENHANCING 1-ALKYLAZACYCLOHEPTAN-2-ONE OR CIS-OLEFINIC FATTY ACID,ESTER, ALCOHOL OR AMINE | PFIZER INC. (US) | 1990-09-25 | — | — | US | claimed |
| JP-62175427-A | — | — | None | — | — | JP | disclosed |
| EP-4674894-A2 | COPOLYMERS OF N-VINYLPYRROLIDONE WITH FUNCTIONALIZED MALEIC ACID MOIETIES | Hemoteq AG (DE) | 2026-01-07 | — | — | EP | disclosed |
| EP-4663688-A2 | CROSSLINKERS | Hemoteq AG (DE) | 2025-12-17 | — | — | EP | disclosed |
| US-4423040-A | Vehicle composition containing 1-substituted azacyclohexan-2-ones | NELSON RESEARCH & DEVELOPMENT COMPANY (US) | 1983-12-27 | — | — | US | disclosed |
| US-4415563-A | TOPICAL APPLICATION OF MEDICINE; COSMETICS | NELSON RESEARCH & DEVELOPMENT COMPANY (US) | 1983-11-15 | — | — | US | disclosed |
| EP-0077078-A1 | Method for improved plant pest control | Whitby Research Incorporated (US) | 1983-04-20 | — | — | EP | disclosed |
| US-4316893-A | USED FOR TOPICAL APPLICATION WITH A PHYSIOLOGICALLY ACTIVE AGENT | NELSON RESEARCH & DEVELOPMENT CO. (US) | 1982-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130245058-A1 | MEDICAL PRODUCT WITH A PARTICLE-FREE COATING RELEASING AN ACTIVE SUBSTANCE | CD44, VEGFA, CD63 | ALOX5 1535/4885GAA 3086/4885FAAH 2847/4885 |
| US-20030134420-A1 | Methods and compositions for gene delivery | POLRMT, NUP205, POLM | ALOX5 4662/4885GAA 1759/4885FAAH 4025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.